A vaccine has been shown for the first time to protect against life-threatening staph infections, a major hazard among hospital patients, researchers said today.
The genetically engineered vaccine was tested first in kidney dialysis patients, and it cut their risk of staph blood poisoning in half for nearly a year.
“I am quite encouraged by this. It could be a major breakthrough in this area,” said Dr. Steve Black of the Kaiser Permanente Vaccine Study Center in Oakland, Calif.
Black presented the results in a last-minute addition to the program of the annual infectious disease meeting of the American Society for Microbiology.
The vaccine, called StaphVAX, was created at the National Institutes of Health and is being developed by Nabi Corp. of Boca Raton, Fla., which financed the latest study.
Staphylococcus aureus is a common and ordinarily harmless inhabitant of the human nasal tract. It can live for days outside the body on almost any surface and spreads widely in hospitals, where it can cause serious infections among those who are already sick, especially if they have weak immune defenses.
Infection Sometimes Fatal
Staph can be deadly if it invades the bloodstream. It can lead to pneumonia, encephalitis, liver abscesses and other problems.
Staph infections are relatively common among people who use needles frequently, such as diabetics and dialysis patients, elderly people in nursing homes and those who are hospitalized for surgery and a variety of other conditions.
Doctors conducted the first large test of StaphVAX in dialysis patients because typically between 1 percent and 3 percent of them get bloodstream staph infections each year.
Robert B. Naso, Nabi’s research director, said the company will seek approval soon from the U.S. Food and Drug Administration to produce and sell the vaccine.
The study enrolled 1,804 patients at 90 dialysis centers in California. Half got the vaccine, while the rest took dummy shots.
The vaccine appeared to quickly lower the risk of staph. After 10 months, there were 11 serious infections among those getting the vaccine, compared with 26 in the unprotected group, a 57 percent reduction.
The vaccine triggers the body to make fresh antibodies against staph. After one year, the patients’ antibody levels dropped, and their protection against staph began to fade.
Dr. Julie Gerberding, head of hospital infections at the U.S. Centers for Disease Control and Prevention, noted that staph is an especially difficult problem for dialysis patients.
A Growing Immunity to Antibiotics
“If you can get this much protection in them, it might work even better in other patients,” she said.
Staph infections are of particular concern because the bacteria is growing immune to the antibiotics commonly used to treat it. Half of all staph that circulates in hospitals is resistant to methicillin, the standard drug. Now it is developing resistance to vancomycin, the main backup drug.
Black said the new vaccine could be given to build up staph resistance in surgery patients, who are prone to the infection. It might also be used in nursing homes, among diabetes patients and in people who are hospitalized for a variety of problems.
The Latest on: Staph Infections
via Google News
The Latest on: Staph Infections
- Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infectionson August 1, 2022 at 5:00 am
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and ...
- Hospital-Acquired Disease Testing Market Analysis Report 2022 - Global Forecast to 2029 - ResearchAndMarkets.comon August 1, 2022 at 1:38 am
The global hospital-acquired disease testing market size is estimated to be USD 1,500.4 million in 2021 and is expected to witness a CAGR of 20.81% during the forecast period. This exhaustive research ...
- New copper material promises to be the superbug fighteron July 30, 2022 at 7:29 am
The new material has “tiny bumps that can kill bacteria by rupturing their cell wall.” It also includes zinc. Tests done on the material revealed that it took just one hour to kill 99.7 percent of ...
- New tool uncovers 'elegant' mechanism responsible for antibiotic tolerance in golden staphon July 25, 2022 at 11:39 am
Researchers have uncovered an elegant system that contributes to antibiotic tolerance in the 'superbug' Staphylococcus aureus, identifying and characterizing a mechanism for drug tolerance and ...
- New understanding of 'superantigens' could lead to improved staph infection treatmentson July 21, 2022 at 1:42 pm
The bacterium Staphylococcus aureus has long been known to cause infections in humans, ranging from mild skin infections to pneumonia to more serious infections of the heart. In high-income countries, ...
- Progression From New Methicillin-resistant Staphylococcus aureus Colonisation to Infectionon July 12, 2022 at 5:00 pm
We sought to investigate the risk of progression to infection over a five year period in a cohort of patients who acquired MRSA during an admission at our hospital.
- Why Staph Vaccines Don’t Work in Humanson July 8, 2022 at 2:34 am
For the most part, the bacterium Staphylococcus aureus is common and harmless, posing no threat to humans with whom they coexist. Occasionally, though, it can become an opportunistic pathogen, causing ...
- Solving the Mystery of Failed Staph Vaccines Shows How to Make Them Effectiveon July 7, 2022 at 9:24 pm
As such, researchers have tried to develop a vaccine that prevents serious staph infection. But so far, every vaccine candidate has failed in human trials. Now, scientists have learned why. The ...
- Familiarity breeds exempt: Why staph vaccines don't work in humanson July 7, 2022 at 11:44 am
Researchers say they may have found the reason why multiple human clinical trials of staphylococcus vaccines have failed: the bacteria knows us too well. For the most part, the bacterium ...
- Researchers unravel mechanism that underlies failure of staph vaccine trialson July 7, 2022 at 11:27 am
For the most part, the bacterium Staphylococcus aureus is common and harmless, posing no threat to humans with whom they coexist. Occasionally, though, it can become an opportunistic pathogen ...
via Bing News